Sign in

CIK 0001628171 · Large accelerated filer

Revolution Medicines, Inc.

Sign in to watch
Ticker
RVMD
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
472029180
Phone
650-481-6801
Business address
700 SAGINAW DR, REDWOOD CITY, CA, 94063

Securities

  • RVMD Common Stock Nasdaq
  • RVMDW Warrant Nasdaq
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$85,328,124
in 21 filings, $85.3M under 10b5-1 plans

Net −$85,328,124. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. GOLDSMITH MARK A −$20.8M See Remarks sold 28% of stake
  2. Kelsey Stephen Michael −$19.8M See Remarks sold 26% of stake
  3. Kim Lorence H. −$15.0M Director sold 100% of stake
  4. Cislini Jeff −$12.7M SVP & General Counsel sold 54% of stake
  5. Anders Jack −$7.5M Chief Financial Officer sold 25% of stake

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-03-02 GOLDSMITH MARK A See Remarks Sale 10b5-1 −1,700 $101.47 $173K 65,224
2026-03-02 GOLDSMITH MARK A See Remarks Sale 10b5-1 −800 $102.00 $82K 64,424
2026-03-02 GOLDSMITH MARK A See Remarks Sale 10b5-1 −100 $98.29 $10K 67,324
2026-03-02 GOLDSMITH MARK A See Remarks Sale 10b5-1 −600 $100.19 $60K 66,724
2026-03-02 GOLDSMITH MARK A See Remarks Sale 10b5-1 −2,100 $101.63 $213K 64,624
2026-03-02 GOLDSMITH MARK A See Remarks Sale 10b5-1 −200 $102.08 $20K 64,424
2026-03-02 GOLDSMITH MARK A See Remarks Option exercise · Stock Option (Right to Buy) 10b5-1 −30,000 47,708
2026-03-01 Wang Xiaolin See Remarks Grant or award +15,100 118,073
2026-03-01 Wang Xiaolin See Remarks Grant or award · Stock Option (Right to Buy) +34,000 34,000
2026-03-01 Wei Lin Chief Medical Officer Grant or award +15,100 103,439
2026-03-01 Wei Lin Chief Medical Officer Grant or award · Stock Option (Right to Buy) +34,000 34,000
2026-03-01 Kelsey Stephen Michael See Remarks Grant or award +21,100 299,700
2026-03-01 Kelsey Stephen Michael See Remarks Grant or award · Stock Option (Right to Buy) +47,600 47,600
2026-03-01 GOLDSMITH MARK A See Remarks Grant or award 10b5-1 +57,100 289,569
2026-03-01 GOLDSMITH MARK A See Remarks Grant or award · Stock Option (Right to Buy) 10b5-1 +128,600 128,600
2026-03-01 Horn Margaret A Chief Operating Officer Grant or award +21,100 162,153
2026-03-01 Horn Margaret A Chief Operating Officer Grant or award · Stock Option (Right to Buy) +47,600 47,600
2026-03-01 Cislini Jeff General Counsel Grant or award +14,500 61,476
2026-03-01 Cislini Jeff General Counsel Grant or award · Stock Option (Right to Buy) +32,500 32,500
2026-03-01 Anders Jack Chief Financial Officer Grant or award +20,200 128,265

Page 12 of 18 · 352 trades